Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Purpose Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment. Prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) decreases the incidence of febrile neutropenia, the rate of hospitalization, and the use of antibiotics in...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2016-05, Vol.24 (5), p.1991-1998 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1998 |
|---|---|
| container_issue | 5 |
| container_start_page | 1991 |
| container_title | Supportive care in cancer |
| container_volume | 24 |
| creator | Nahon, Sophie Rastkhah, Mansour Ben Abdelghani, Meher Soumoudronga, Ravaka-Fatoma Gasnereau, Isabelle Labourey, Jean-Luc |
| description | Purpose
Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment. Prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) decreases the incidence of febrile neutropenia, the rate of hospitalization, and the use of antibiotics in patients at risk. The aim of this study was to assess efficacy, safety, and use of Zarzio
®
—biosimilar of Neupogen
®
(G-CSF; filgrastim)—in prophylaxis of chemotherapy-induced neutropenia in current practice in cancer patients.
Methods
We conducted an observational, prospective, longitudinal, and multicentric study in France. The incidence of neutropenia was evaluated at each cycle of chemotherapy.
Results
One hundred eighty-four patients (women, 64.7 %; mean age, 61.7 years) with solid tumor (89.7 %; breast cancer, 50.5 %) or non-Hodgkin lymphoma (10.3 %) were included. The risk of febrile neutropenia based on chemotherapy regimen was >20 % for 32.1 % of patients. No case of febrile neutropenia was reported. Neutropenia was the cause of hospitalization and/or antibiotic therapy in 10 patients. The most frequent adverse events related to Zarzio
®
were pain, in particular bone pain. No serious adverse event related to Zarzio
®
was reported.
Conclusion
The results obtained in real-life conditions confirm that Zarzio
®
is efficient and well tolerated in cancer patients. |
| doi_str_mv | 10.1007/s00520-015-2986-0 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4805722</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>26507190</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-9db8045cfc4a972575ab5ff57d69490aec76b6431c04bcf151a70c5370ee449f3</originalsourceid><addsrcrecordid>eNp9kUGOFCEYhYnROO3oAdwYDjDoDwVF48LETBw1mcSNbtwQioIuJlVQgaqJ7TW8h4fwZFK2TnTjiuR_73vA_xB6SuE5BZAvCoBgQIAKwtS-JXAP7ShvGiKbRt1HO1CcEt4IcYYelXIDQKUU7CE6Y60ASRXs0LfPJn8N6cf3C9yFVMIURpNx8tiH8ZBNWcJ0gUPEc07zcBzNl1A21Q5uSsvgspmPJMR-ta7H0a1LtbkYzIbktC4huooauwTrXmKDr7KLdtjSyuzq9NbhaR03NS45WFyWtT8-Rg-8GYt78vs8R5-u3ny8fEeuP7x9f_n6mljO2UJU3-2BC-stN0oyIYXphPdC9q3iCoyzsu1a3lALvLOeCmokWNFIcI5z5Ztz9OqUO6_d5PpfbzCjnnOYTD7qZIL-V4lh0Id0q_kehGSsBtBTgK3_Kdn5O5aC3hrSp4Z0bUhvDWmozLO_L70j_lRSDexkKFWKB5f1TVpzrIv4T-pPslmiag</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Nahon, Sophie ; Rastkhah, Mansour ; Ben Abdelghani, Meher ; Soumoudronga, Ravaka-Fatoma ; Gasnereau, Isabelle ; Labourey, Jean-Luc</creator><creatorcontrib>Nahon, Sophie ; Rastkhah, Mansour ; Ben Abdelghani, Meher ; Soumoudronga, Ravaka-Fatoma ; Gasnereau, Isabelle ; Labourey, Jean-Luc</creatorcontrib><description>Purpose
Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment. Prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) decreases the incidence of febrile neutropenia, the rate of hospitalization, and the use of antibiotics in patients at risk. The aim of this study was to assess efficacy, safety, and use of Zarzio
®
—biosimilar of Neupogen
®
(G-CSF; filgrastim)—in prophylaxis of chemotherapy-induced neutropenia in current practice in cancer patients.
Methods
We conducted an observational, prospective, longitudinal, and multicentric study in France. The incidence of neutropenia was evaluated at each cycle of chemotherapy.
Results
One hundred eighty-four patients (women, 64.7 %; mean age, 61.7 years) with solid tumor (89.7 %; breast cancer, 50.5 %) or non-Hodgkin lymphoma (10.3 %) were included. The risk of febrile neutropenia based on chemotherapy regimen was >20 % for 32.1 % of patients. No case of febrile neutropenia was reported. Neutropenia was the cause of hospitalization and/or antibiotic therapy in 10 patients. The most frequent adverse events related to Zarzio
®
were pain, in particular bone pain. No serious adverse event related to Zarzio
®
was reported.
Conclusion
The results obtained in real-life conditions confirm that Zarzio
®
is efficient and well tolerated in cancer patients.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-015-2986-0</identifier><identifier>PMID: 26507190</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Antineoplastic Agents - adverse effects ; Antineoplastic Combined Chemotherapy Protocols ; Biosimilar Pharmaceuticals - administration & dosage ; Biosimilar Pharmaceuticals - adverse effects ; Chemotherapy-Induced Febrile Neutropenia - diagnosis ; Chemotherapy-Induced Febrile Neutropenia - epidemiology ; Chemotherapy-Induced Febrile Neutropenia - etiology ; Chemotherapy-Induced Febrile Neutropenia - prevention & control ; Female ; Filgrastim - administration & dosage ; Filgrastim - adverse effects ; France - epidemiology ; Hematologic Agents - administration & dosage ; Hematologic Agents - adverse effects ; Humans ; Incidence ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Musculoskeletal Pain - chemically induced ; Neoplasms - drug therapy ; Nursing ; Nursing Research ; Oncology ; Original ; Original Article ; Pain Medicine ; Prospective Studies ; Rehabilitation Medicine ; Treatment Outcome</subject><ispartof>Supportive care in cancer, 2016-05, Vol.24 (5), p.1991-1998</ispartof><rights>The Author(s) 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-9db8045cfc4a972575ab5ff57d69490aec76b6431c04bcf151a70c5370ee449f3</citedby><cites>FETCH-LOGICAL-c442t-9db8045cfc4a972575ab5ff57d69490aec76b6431c04bcf151a70c5370ee449f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-015-2986-0$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-015-2986-0$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,778,782,883,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26507190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nahon, Sophie</creatorcontrib><creatorcontrib>Rastkhah, Mansour</creatorcontrib><creatorcontrib>Ben Abdelghani, Meher</creatorcontrib><creatorcontrib>Soumoudronga, Ravaka-Fatoma</creatorcontrib><creatorcontrib>Gasnereau, Isabelle</creatorcontrib><creatorcontrib>Labourey, Jean-Luc</creatorcontrib><title>Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Purpose
Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment. Prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) decreases the incidence of febrile neutropenia, the rate of hospitalization, and the use of antibiotics in patients at risk. The aim of this study was to assess efficacy, safety, and use of Zarzio
®
—biosimilar of Neupogen
®
(G-CSF; filgrastim)—in prophylaxis of chemotherapy-induced neutropenia in current practice in cancer patients.
Methods
We conducted an observational, prospective, longitudinal, and multicentric study in France. The incidence of neutropenia was evaluated at each cycle of chemotherapy.
Results
One hundred eighty-four patients (women, 64.7 %; mean age, 61.7 years) with solid tumor (89.7 %; breast cancer, 50.5 %) or non-Hodgkin lymphoma (10.3 %) were included. The risk of febrile neutropenia based on chemotherapy regimen was >20 % for 32.1 % of patients. No case of febrile neutropenia was reported. Neutropenia was the cause of hospitalization and/or antibiotic therapy in 10 patients. The most frequent adverse events related to Zarzio
®
were pain, in particular bone pain. No serious adverse event related to Zarzio
®
was reported.
Conclusion
The results obtained in real-life conditions confirm that Zarzio
®
is efficient and well tolerated in cancer patients.</description><subject>Aged</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Biosimilar Pharmaceuticals - administration & dosage</subject><subject>Biosimilar Pharmaceuticals - adverse effects</subject><subject>Chemotherapy-Induced Febrile Neutropenia - diagnosis</subject><subject>Chemotherapy-Induced Febrile Neutropenia - epidemiology</subject><subject>Chemotherapy-Induced Febrile Neutropenia - etiology</subject><subject>Chemotherapy-Induced Febrile Neutropenia - prevention & control</subject><subject>Female</subject><subject>Filgrastim - administration & dosage</subject><subject>Filgrastim - adverse effects</subject><subject>France - epidemiology</subject><subject>Hematologic Agents - administration & dosage</subject><subject>Hematologic Agents - adverse effects</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Musculoskeletal Pain - chemically induced</subject><subject>Neoplasms - drug therapy</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Prospective Studies</subject><subject>Rehabilitation Medicine</subject><subject>Treatment Outcome</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kUGOFCEYhYnROO3oAdwYDjDoDwVF48LETBw1mcSNbtwQioIuJlVQgaqJ7TW8h4fwZFK2TnTjiuR_73vA_xB6SuE5BZAvCoBgQIAKwtS-JXAP7ShvGiKbRt1HO1CcEt4IcYYelXIDQKUU7CE6Y60ASRXs0LfPJn8N6cf3C9yFVMIURpNx8tiH8ZBNWcJ0gUPEc07zcBzNl1A21Q5uSsvgspmPJMR-ta7H0a1LtbkYzIbktC4huooauwTrXmKDr7KLdtjSyuzq9NbhaR03NS45WFyWtT8-Rg-8GYt78vs8R5-u3ny8fEeuP7x9f_n6mljO2UJU3-2BC-stN0oyIYXphPdC9q3iCoyzsu1a3lALvLOeCmokWNFIcI5z5Ztz9OqUO6_d5PpfbzCjnnOYTD7qZIL-V4lh0Id0q_kehGSsBtBTgK3_Kdn5O5aC3hrSp4Z0bUhvDWmozLO_L70j_lRSDexkKFWKB5f1TVpzrIv4T-pPslmiag</recordid><startdate>20160501</startdate><enddate>20160501</enddate><creator>Nahon, Sophie</creator><creator>Rastkhah, Mansour</creator><creator>Ben Abdelghani, Meher</creator><creator>Soumoudronga, Ravaka-Fatoma</creator><creator>Gasnereau, Isabelle</creator><creator>Labourey, Jean-Luc</creator><general>Springer Berlin Heidelberg</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20160501</creationdate><title>Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study</title><author>Nahon, Sophie ; Rastkhah, Mansour ; Ben Abdelghani, Meher ; Soumoudronga, Ravaka-Fatoma ; Gasnereau, Isabelle ; Labourey, Jean-Luc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-9db8045cfc4a972575ab5ff57d69490aec76b6431c04bcf151a70c5370ee449f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Biosimilar Pharmaceuticals - administration & dosage</topic><topic>Biosimilar Pharmaceuticals - adverse effects</topic><topic>Chemotherapy-Induced Febrile Neutropenia - diagnosis</topic><topic>Chemotherapy-Induced Febrile Neutropenia - epidemiology</topic><topic>Chemotherapy-Induced Febrile Neutropenia - etiology</topic><topic>Chemotherapy-Induced Febrile Neutropenia - prevention & control</topic><topic>Female</topic><topic>Filgrastim - administration & dosage</topic><topic>Filgrastim - adverse effects</topic><topic>France - epidemiology</topic><topic>Hematologic Agents - administration & dosage</topic><topic>Hematologic Agents - adverse effects</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Musculoskeletal Pain - chemically induced</topic><topic>Neoplasms - drug therapy</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Prospective Studies</topic><topic>Rehabilitation Medicine</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nahon, Sophie</creatorcontrib><creatorcontrib>Rastkhah, Mansour</creatorcontrib><creatorcontrib>Ben Abdelghani, Meher</creatorcontrib><creatorcontrib>Soumoudronga, Ravaka-Fatoma</creatorcontrib><creatorcontrib>Gasnereau, Isabelle</creatorcontrib><creatorcontrib>Labourey, Jean-Luc</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nahon, Sophie</au><au>Rastkhah, Mansour</au><au>Ben Abdelghani, Meher</au><au>Soumoudronga, Ravaka-Fatoma</au><au>Gasnereau, Isabelle</au><au>Labourey, Jean-Luc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2016-05-01</date><risdate>2016</risdate><volume>24</volume><issue>5</issue><spage>1991</spage><epage>1998</epage><pages>1991-1998</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Purpose
Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment. Prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) decreases the incidence of febrile neutropenia, the rate of hospitalization, and the use of antibiotics in patients at risk. The aim of this study was to assess efficacy, safety, and use of Zarzio
®
—biosimilar of Neupogen
®
(G-CSF; filgrastim)—in prophylaxis of chemotherapy-induced neutropenia in current practice in cancer patients.
Methods
We conducted an observational, prospective, longitudinal, and multicentric study in France. The incidence of neutropenia was evaluated at each cycle of chemotherapy.
Results
One hundred eighty-four patients (women, 64.7 %; mean age, 61.7 years) with solid tumor (89.7 %; breast cancer, 50.5 %) or non-Hodgkin lymphoma (10.3 %) were included. The risk of febrile neutropenia based on chemotherapy regimen was >20 % for 32.1 % of patients. No case of febrile neutropenia was reported. Neutropenia was the cause of hospitalization and/or antibiotic therapy in 10 patients. The most frequent adverse events related to Zarzio
®
were pain, in particular bone pain. No serious adverse event related to Zarzio
®
was reported.
Conclusion
The results obtained in real-life conditions confirm that Zarzio
®
is efficient and well tolerated in cancer patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>26507190</pmid><doi>10.1007/s00520-015-2986-0</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2016-05, Vol.24 (5), p.1991-1998 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4805722 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Antineoplastic Agents - adverse effects Antineoplastic Combined Chemotherapy Protocols Biosimilar Pharmaceuticals - administration & dosage Biosimilar Pharmaceuticals - adverse effects Chemotherapy-Induced Febrile Neutropenia - diagnosis Chemotherapy-Induced Febrile Neutropenia - epidemiology Chemotherapy-Induced Febrile Neutropenia - etiology Chemotherapy-Induced Febrile Neutropenia - prevention & control Female Filgrastim - administration & dosage Filgrastim - adverse effects France - epidemiology Hematologic Agents - administration & dosage Hematologic Agents - adverse effects Humans Incidence Male Medicine Medicine & Public Health Middle Aged Musculoskeletal Pain - chemically induced Neoplasms - drug therapy Nursing Nursing Research Oncology Original Original Article Pain Medicine Prospective Studies Rehabilitation Medicine Treatment Outcome |
| title | Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T17%3A10%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Zarzio%C2%AE,%20biosimilar%20of%20filgrastim,%20in%20prophylaxis%20of%20chemotherapy-induced%20neutropenia%20in%20routine%20practice:%20a%20French%20prospective%20multicentric%20study&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Nahon,%20Sophie&rft.date=2016-05-01&rft.volume=24&rft.issue=5&rft.spage=1991&rft.epage=1998&rft.pages=1991-1998&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-015-2986-0&rft_dat=%3Cpubmed_cross%3E26507190%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26507190&rfr_iscdi=true |